Amarantus BioSciences announces close of convertible bridge note

Amarantus Biosciences, a biotechnology company developing MANF, a first-in-class, disease-modifying therapeutic protein that addresses an underlying form of cell death known as apoptosis, announced today that it has completed a bridge facility with Atlantic Partners in the aggregate amount of $150,000. The note consists of a six month interest bearing security and equity participation. Atlantic Partners is a financing group headed by Dr. Samuel Herschkowitz and Joshua Kornberg dedicated to enhancing shareholder value and assisting companies in fund raising efforts. Concurrent with this facility, Dr. Herschkowitz will serve as an advisor to the Board of Directors.

“This bridge facility was not only done to secure interim financing, but also to engage the Atlantic Group to expand the our knowledge base to fully develop our corporate strategy for regulatory approval of our MANF treatment for Parkinson’s Disease,” said Martin D. Cleary, Chairman & CEO of Amarantus. “We hope to gain from Dr. Herschkowitz’ deep network of industry contacts to bolster corporate interest in our product development programs.”

Since 1982, Dr. Samuel Herschkowitz has been a known leader in the area of biotechnology, healthcare devices and pharmaceutical development. Dr. Herschkowitz has participated in the development of many biotechnology innovations. He was one of the original investors in Theragenics Corporation, a New York Stock Exchange company, which innovated the development of high energy, short duration, radioactive seeds for the treatment of prostate cancer. He is also a founder of Delcath Systems, a NASDAQ company, specializing in the delivery of high dose chemotherapy to targeted area of cancer growth. He has provided early seed investment money and bridge financing for companies such as Perceptive Systems, Oncogene Sciences and, most recently, Serenity Pharmaceuticals.

Presently, Dr. Herschkowitz is the Chief utive Office of Serenity Pharmaceuticals which specializes in the commercialization of urological pharmaceuticals. In addition, from 1982 until 2001, Dr. Herschkowitz was a general partner of two venture capital funds, Banipal and Venkol ventures, which specialized in the investment in health care technology and pharmaceuticals.

Kornberg is a founding partner of GPF, a private equity fund. Prior to founding GPF, Kornberg served as Chief Investment Officer of The Lightstone Group, a national private equity firm and Director of the Lightstone Value Plus REIT, a public company focused on commercial real estate. Prior to joining Lightstone, Kornberg served as a Director at ARK Realty Investors, a real estate investment and development firm. Mr. Kornberg worked in the capital markets group at Morgan Stanley. In addition, he served as Vice President at The RREEF Funds, one of the leading global pension fund advisors. Mr. Kornberg has implemented investment strategies for numerous operating companies and has led the origination and structuring of approximately $10 billion of deal value including entity level and related financings.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

Subscribe Newsletter
To Top